Arcutis Biotherapeutics (ARQT) Assets Average (2020 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Assets Average of $446.5 million for Q1 2026, up 28.86% year-over-year from $346.5 million in Q1 2025, and up 11.07% quarter-over-quarter from $402.0 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) Assets Average (2020 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Assets Average history runs 7 years deep, the most recent figure standing at $446.5 million for Q1 2026.
- In Q1 2026, Assets Average rose 28.86% year-over-year to $446.5 million; the TTM figure through Mar 2026 stood at $446.5 million (up 28.86% YoY), while the FY2025 annual figure was $390.9 million, up 13.27% from the prior year.
- Assets Average for Q1 2026 stood at $446.5 million, up from $402.0 million in the prior quarter.
- The five-year high for Assets Average was $479.1 million in Q4 2022, with the low at $306.8 million in Q3 2023.
- The 5-year median for Assets Average is $393.1 million (2024), against an average of $388.3 million.
- The sharpest annual moves came in 2023 and 2024: Assets Average sank 33.8% in 2023, then surged 43.75% in 2024.
- Arcutis Biotherapeutics' Assets Average stood at $479.1 million in 2022, then slumped by 33.8% to $317.2 million in 2023, then climbed by 23.95% to $393.1 million in 2024, then grew by 2.25% to $402.0 million in 2025, then grew by 11.07% to $446.5 million in 2026.
- Business Quant data shows ARQT's Assets Average at $446.5 million in Q1 2026, $402.0 million in Q4 2025, and $361.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 474.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 474.27 Mn |
| Mar 31, 2026 | 446.49 Mn |
| Dec 31, 2025 | 401.98 Mn |
| Sep 30, 2025 | 361.71 Mn |
| Jun 30, 2025 | 348.27 Mn |
| Mar 31, 2025 | 346.50 Mn |
| Dec 31, 2024 | 393.12 Mn |
| Sep 30, 2024 | 441.06 Mn |
| Jun 30, 2024 | 461.65 Mn |
| Mar 31, 2024 | 409.95 Mn |
| Dec 31, 2023 | 317.16 Mn |
| Sep 30, 2023 | 306.82 Mn |
| Jun 30, 2023 | 350.07 Mn |
| Mar 31, 2023 | 414.37 Mn |
| Dec 31, 2022 | 479.09 Mn |
| Sep 30, 2022 | 404.69 Mn |
| Jun 30, 2022 | 332.29 Mn |
| Mar 31, 2022 | 386.13 Mn |
| Dec 31, 2021 | 397.58 Mn |
| Sep 30, 2021 | 409.95 Mn |